A Translational Research Resource Centre and Image-Based Screening Platform for MRC-LMCB, UCL.

Lead Research Organisation: MRC Cell Biology Unit

Abstract

We propose to establish a Translational Research Resource Centre at the MRC-Laboratory for Molecular Biology/Cell Biology Unit (LMCB/CBU) that will provide know-how and technical platforms for the MRC, UCL and the surrounding research community to facilitate and develop the translation of basic research. The initial platform will be an automated image-based high through-put screening system, coupled with the technique of RNA interference (RNAi), which has now become one of the most powerful methods for identifying genes/proteins involved in a variety of cellular pathways and pathological conditions. The same assays and equipment can be used to screen small compound libraries, thus allowing not only the identification of novel targets for drug development but also lead compounds for a range of genetic and infectious diseases as well as conditions such as cancer, neuro-degeneration and visual failure. Major programmes of this sort are already underway elsewhere in Europe and the USA. Our program will bring these key new technologies to the MRC and the UCL communities - one of the largest concentrations of biomedical research in the UK.

Technical Summary

We propose to establish a Translational Research Resource Centre in the MRC-Laboratory for Molecular Biology/Cell Biology Unit that exploits our expertise in cell biology and imaging to enhance and develop the translation of basic biomedical research to applications. The Centre will provide a resource for the MRC, UCL and other local/affiliated institutions through which expert partners can be found to link basic research to identified human disease candidates. The MRC-LMCB is well placed to provide the expert skills and the technical resource base to make these links. The three main goals will be: -

1) To facilitate translation of basic research outcomes
2) To provide expert research and technical resources to determine the mechanism /function of identified candidates in human disease
3) To implement emerging technologies to enhance translational research outcomes

An initial technical platform to support these activities will be a fully automated high through-put image-based screening system for RNAi and small compound libraries to identify novel drug targets and lead compounds relevant for a range of conditions and diseases including infectious disease (HIV), cancer growth, metastasis and invasion, visual failure, neural degeneration and genetic disease, inflammation, haemostasis, and metabolic diseases. A number of these platforms have been established in the USA and elsewhere in Europe but have not been developed extensively in the UK and are not available within UCL or the MRC.

Publications

10 25 50
 
Description Document on the implications of Brexit on research funding at UCL
Geographic Reach Europe 
Policy Influence Type Gave evidence to a government review
 
Description Member of expert panel advising the Dementia Discovery Fund for potential investments in autophagy research
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Michael J Fox Foundation Parkin Consortium
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Scientific Advisor to AstraZeneca High-Content Biology
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description The Royal Society Newton Fellowship panel member
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Action Medical Research PhD Fellowship
Amount £230,000 (GBP)
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2018
 
Description BBSRC
Amount £352,900 (GBP)
Funding ID BB/L021404/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
End 09/2017
 
Description BBSRC New Investigator Scheme
Amount £255,375 (GBP)
Funding ID BB/JO15881/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2013 
End 12/2015
 
Description Dementia Platform UK
Amount £1,900,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2015 
End 03/2016
 
Description Drugs4Targets
Amount € 5,000 (EUR)
Organisation Bayer 
Department Bayer HealthCare
Sector Private
Country Germany
Start 08/2012 
End 07/2013
 
Description EU FP7 Innovative Medicines
Amount € 6,000,000 (EUR)
Funding ID HIVINNOV 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start  
End 10/2015
 
Description EU Marie-Curie Reintegration Fund
Amount € 50,000 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 04/2011 
End 03/2013
 
Description MRC Centre for Medical and Molecular Virology
Amount £2,778,000 (GBP)
Funding ID G0900950 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
End 11/2014
 
Description Marie-Curie International Incoming Fellow
Amount € 221,606 (EUR)
Organisation European Commission 
Department Seventh Framework Programme (FP7)
Sector Public
Country European Union (EU)
Start 03/2014 
End 03/2016
 
Description Michael J Fox Foundation
Amount $78,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2014 
End 12/2014
 
Description Multi-user equipment grant
Amount £85,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2013 
End 05/2015
 
Description New Investigator Scheme
Amount £252,797 (GBP)
Funding ID BB/J015881/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
 
Description TDRF
Amount £151,213 (GBP)
Funding ID BB/P027431/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 02/2019
 
Description UCL Capital Investment Fund
Amount £150,000 (GBP)
Organisation University College London 
Department School of Life and Medical Sciences
Sector Academic/University
Country United Kingdom
Start 01/2010 
End 12/2010
 
Description UCL Capital Investment Fund
Amount £150,000 (GBP)
Funding ID FK20 
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 01/2010 
End 12/2011
 
Description UCL Confidence in Concept Award
Amount £99,208 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2014 
End 05/2015
 
Description UCL Confidence in Concept Award
Amount £99,753 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2013 
End 05/2014
 
Description UCL Eisai collaboration
Amount £5,000,000 (GBP)
Organisation Eisai Ltd 
Sector Private
Country Japan
Start 11/2017 
End 04/2019
 
Description UCL MRC Confidence in Concepts
Amount £99,208 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC Confidence in Concept Scheme
Sector Academic/University
Country United Kingdom
Start 06/2014 
End 05/2015
 
Description UCL MRC Confidence in Concepts
Amount £99,753 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2013 
End 05/2014
 
Description UCL Therapeutic Innovation Fund
Amount £50,000 (GBP)
Funding ID FKHM 
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 06/2010 
End 05/2011
 
Description UCL-Eisai Collaboration
Amount £12,500 (GBP)
Organisation Eisai Ltd 
Sector Private
Country Japan
Start 10/2016 
End 03/2017
 
Description University of Pennsylvania Orphan Disease Center
Amount $51,020 (USD)
Funding ID MDBR-19-102-BPAN 
Organisation University of Pennsylvania 
Sector Academic/University
Country United States
Start 02/2019 
End 01/2020
 
Description WT Institutional Strategic Support Fund
Amount £65,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2015 
End 12/2017
 
Description WT Multi-user equipment grant
Amount £170,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2013 
End 07/2014
 
Title ATG4ABC CRISPR knockout cell line 
Description HeLa cells with knockout of three proteins (ATG4A, B and C) generated by CRISPR/Cas9 genome editing 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? Yes  
Impact This cell line will be useful for further research into the function of ATG4 proteases and can be used in early stage drug discovery for target validation. 
 
Title Induced pluripotent stem cells from patients with BPAN disease 
Description We generated human induced pluripotent stem cells from patients with BPAN disease. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2019 
Provided To Others? No  
Impact We are currently screening small molecule libraries to identify potential hit compounds with therapeutic benefit. The cells are available upon request. 
 
Title Inhibitor and activator compounds of ATG4B protease. 
Description We have identified inhibitors, as well as activators of the autophagy protease ATG4B. 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? No  
Impact These compounds have therapeutic potential and we are further developing them into lead compounds for the treatment of cancer. 
 
Title Inhibitor compounds of CLK2 kinase 
Description We have identified chemical probes that inhibit proteins of the CLK2 family of proteins. 
Type Of Material Technology assay or reagent 
Year Produced 2016 
Provided To Others? Yes  
Impact The CLK2 inhibitors will provide useful tools to study the function of these proteins and can be used in drug discovery. 
 
Title Modified luciferase release assay 
Description This new version of a luciferase-based assay to monitor autophagy protease ATG4 activity can be used in academic research and drug target identification. The new version includes assays to monitor other protein targets of ATG4, such as LC3A and mutants thereof. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact We have given the plasmid encoding this reporter to several other research groups. We are actively sharing this reagents with multiple labs and hope that this will advance research in this field. 
 
Description ARUK DDI 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution The UKDP is working closely with the ARUK Drug Discovery Institute with the aim to develop novel therapies for neurodegenerative disorders. Both networks collaborate closely in terms of drug discovery research and through exchange of knowledge, equipment and technologies.
Collaborator Contribution The UKDP is working closely with the ARUK Drug Discovery Institute with the aim to develop novel therapies for neurodegenerative disorders. Both networks collaborate closely in terms of drug discovery research and through exchange of knowledge, equipment and technologies.
Impact None yet
Start Year 2017
 
Description ATG4B compounds BC Cancer Agency 
Organisation British Columbia Cancer Agency (BCCA)
Country Canada 
Sector Public 
PI Contribution We are assaying compounds that inhibit autophagy in our cell-based assays.
Collaborator Contribution Provision of chemical compounds for testing.
Impact No outcomes yet.
Start Year 2014
 
Description Adhiron-based inhibitors of Grb2 signaling 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution We are studying Grb2-mediated signaling pathways using non-antibody based inhibitors.
Collaborator Contribution Provision of non-antibody based binding proteins of Grb2.
Impact No outputs yet.
Start Year 2013
 
Description Arrayed CRISPR Library Screening 
Organisation Thermo Fisher Scientific
Country United States 
Sector Private 
PI Contribution We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher.
Collaborator Contribution ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project.
Impact We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016.
Start Year 2015
 
Description Arrayed CRISPR library screening 
Organisation Thermo Fisher Scientific
Country United States 
Sector Private 
PI Contribution "We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher."
Collaborator Contribution "ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project."
Impact "We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016."
Start Year 2015
 
Description CDI 
Organisation Government of Wales
Department Cadw
Country United Kingdom 
Sector Public 
PI Contribution Provision of cell-based assays for autophagy.
Collaborator Contribution Provision of induced pluripotent stem cell-derived neurons for the development of autophagy assays.
Impact Research data being generated.
Start Year 2012
 
Description Cellular Dynamics International 
Organisation Cellular Dynamics
Country United States 
Sector Private 
PI Contribution Expertise in high-content screening of primary neurons
Collaborator Contribution Provision of iPS-derived neurons.
Impact None to date.
Start Year 2012
 
Description Chemistry of ATG4B Inhibitors 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution We have developed cell-based and in vitro assays to monitor autophagy protease activity. We work with researchers at UCL for provision of chemical libraries and chemistry to enable drug discovery projects.
Collaborator Contribution Provision of chemical compounds and expertise in chemistry.
Impact This partnership is multi-disciplinary and involves chemistry, biology and bioinformatics.
Start Year 2014
 
Description Darren Tomlinson, University of Leeds 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution Assays for EGFR/Grb2 signaling and binding studies
Collaborator Contribution Provision of non-antibody binding protein inhibitors of Grb2
Impact None to date
Start Year 2013
 
Description David Selwood, UCL 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Small molecule screening and drug discovery
Collaborator Contribution Provision of small molecule library Chemibank
Impact None to date
Start Year 2010
 
Description Dr Marcus Dorner, Imperial College 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided data and expertise on the effect of Hsp90 on regulation of HIV-1 latency, provided specific Hsp90 inhibitor.
Collaborator Contribution humanized mouse models for HIV-1 infection to test the effect of selective Hsp90 inhibitors on HIV-1 latency.
Impact experiments ongoing.
Start Year 2014
 
Description Dr. Lee Hwee Kuan 
Organisation Agency for Science, Technology and Research (A*STAR)
Department Bioinformatics institute (BII)
Country Singapore 
Sector Academic/University 
PI Contribution Joint supervision of William Grimes PhD student with Prof Dan Cutler
Collaborator Contribution Joint supervision and provides Singapore International Graduate Award (SINGA) for PhD student William Grimes.
Impact n/a
Start Year 2013
 
Description Dr. Peter Cherepanov, CRUK 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Provision of expression constructs, recombiinant protein expression vectors and methods for immunoprecipitation. Expertise on nuclear transport receptors.
Collaborator Contribution Structural biology of Transportin 3
Impact one paper in PNAS: Maertens, G. N., Cook, N. J., Wang, W., Hare, S., Gupta, S. S., Oztop, I., Lee, K., Pye, V. E., Cosnefroy, O., Snijders, A. P., Kewalramani, V. N., Fassati, A., Engelman, A., Cherepanov, P. (2014). Structural basis for nuclear import of splicing factors by human Transportin 3. Proc Natl Acad Sci U S A doi:10.1073/pnas.1320755111. Author URL Zaitseva, L., Cherepanov, P., Leyens, L., Wilson, S. J., Rasaiyaah, J., Fassati, A. (2009). HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome. Retrovirology 6, 11- doi:10.1186/1742-4690-6-11.
Start Year 2010
 
Description Dr. Richard Benarous, Mutabilis, France 
Organisation University College London
Department Metbolism and Endocrinology
Country United Kingdom 
Sector Academic/University 
PI Contribution Performed novel high through put screening to identify host factors necessary for HIV-1 replication.
Collaborator Contribution Provided expertise and library of 10,000 small chemical compounds selected from a 150,000 compounds library.
Impact Identified four new compounds with antiretroviral activity: they belong to a new class of antiretrovirals.
Start Year 2012
 
Description Dr. Veronique Birault, GSK, Stevenage 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Provided data on a new host factor to be used as an antiretroviral target with novel mechanism of action.
Collaborator Contribution Provided lead compounds that target the new host factor discovered by us.
Impact In the process of performing SAR studies with GSK compounds
Start Year 2013
 
Description Eisai Pharmaceuticals 
Organisation Eisai Ltd
Department Eisai London Research Laboratories
Country United Kingdom 
Sector Private 
PI Contribution expertise in HTS of autophagy/mitophagy
Collaborator Contribution Provision of cDNA library and small molecule compounds
Impact None
Start Year 2013
 
Description Eisai Pharmaceuticals 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution In collaboration with researchers at Eisai and funded through the Michael J Fox Foundation, we are exploring the role of De-ubiquitinating enzymes in Parkin-mediated mitophagy. We are providing the underlying cell biology for this study.
Collaborator Contribution Provision of a cDNA library and expertise in the field of neuro-degeneration. This has led to funding from the Michael J Fox Foundation for a pilot project. Since 2017, the partner has provided substantial funding for an early stage drug discovery project in my lab. This project has been initiated in 2017 and is ongoing.
Impact This collaboration has led to two successful funding applications. One is with the Michael J Fox Foundation. The other is with the industry partner itself, which is funding an early stage drug discovery project and a Postdoctoral scientist in the lab.
Start Year 2013
 
Description Johnson & Johnson 
Organisation Johnson & Johnson
Country United States 
Sector Private 
PI Contribution We are screening a small molecule library from J&J with the aim to identify tool compounds that modulate breast cancer cell growth and autophagy.
Collaborator Contribution We have received a small molecule library targeting cysteine proteases for screening.
Impact Exchange of know-how and materials.
Start Year 2017
 
Description Knockout Cell Panel Screening 
Organisation Horizon Genomics
Country United Kingdom 
Sector Private 
PI Contribution "We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening."
Collaborator Contribution "Provision of knockout cell lines and knockout cell panels free of charge."
Impact "We are preparing experiments for publication."
Start Year 2015
 
Description Knockout Cell Panel Screening 
Organisation Horizon Genomics
Country United Kingdom 
Sector Private 
PI Contribution We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening.
Collaborator Contribution Provision of knockout cell lines and knockout cell panels free of charge.
Impact We are preparing experiments for publication.
Start Year 2015
 
Description MRC-T 
Organisation MRC-Technology
Country United Kingdom 
Sector Academic/University 
PI Contribution Small molecule screening and drug discovery
Collaborator Contribution Provision of small molecule library
Impact None to date
Start Year 2010
 
Description MRCT Index Compound Set 
Organisation MRC-Technology
Country United Kingdom 
Sector Academic/University 
PI Contribution High-throughput screening of small molecule compounds
Collaborator Contribution Provision of small molecule library
Impact None to date
Start Year 2015
 
Description MRCT Index Compound Set 
Organisation MRC-Technology
Country United Kingdom 
Sector Academic/University 
PI Contribution High-throughput screening of small molecule compounds"
Collaborator Contribution "Provision of small molecule library"
Impact None to date
Start Year 2015
 
Description MaMTH EGFR Interactions 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution We are studying novel interaction partners of the EGFR that were identified using a technology developed in Igor Stagljar's lab at University of Toronto.
Collaborator Contribution Access to MaMTH, a novel method to identify protein-protein interactions.
Impact A publication has been published: Petschnigg et al. J Mol Biol 2017.
Start Year 2014
 
Description Marcel Jaspars, Univ Aberdeen 
Organisation University of Aberdeen
Country United Kingdom 
Sector Academic/University 
PI Contribution Small molecule screening and drug discovery
Collaborator Contribution Provision of small molecule library, marine natural products
Impact None to date
Start Year 2012
 
Description Medicinal Chemistry of Autophagy modulators 
Organisation University College London
Department School of Pharmacy
Country United Kingdom 
Sector Academic/University 
PI Contribution "Testing small molecule compounds generated by the School of Pharmacy in autophagy assays."
Collaborator Contribution "Generation and provision of 26 compounds for drug discovery."
Impact "Invention Declaration Form has been filed with UCL-B."
Start Year 2015
 
Description Medicinal Chemistry of Autophagy modulators 
Organisation University College London
Department School of Pharmacy
Country United Kingdom 
Sector Academic/University 
PI Contribution Testing small molecule compounds generated by the School of Pharmacy in autophagy assays.
Collaborator Contribution Generation and provision of 60 compounds for drug discovery.
Impact Invention Declaration Form has been filed with UCL-B. Discussions about licensing of compounds with industry partners started.
Start Year 2015
 
Description PerkinElmer 
Organisation Perkin Elmer
Country United States 
Sector Private 
PI Contribution Closely working together on the development of high-content screening technologies. We provide expertise and knowledge.
Collaborator Contribution We have received free hardware and software upgrades, e.g. free 5x objective and software upgrades.
Impact This has enabled the use of additional technologies on the platform, e.g. Presiscan, FRET.
Start Year 2017
 
Description Prof. Charles Bangham, Imperial College 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Discovered new host factor involved in HIV-1 replication that affects integration site selection.
Collaborator Contribution High through put sequencing of HIV-1 integration sites.
Impact one paper in preparation, one grant application submitted to MRC.
Start Year 2012
 
Description Prof. Christopher Moody and Dr. Russell Kitson, University of Nottingham 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided data and expertise on the role of Hsp90 in HIV-1 latency.
Collaborator Contribution Provided new chemical compounds, inhibitors of Hsp90.
Impact one paper in PNAS: Anderson, I., Low, J. S., Weston, S., Weinberger, M., Zhyvoloup, A., Labokha, A. A., Corazza, G., Kitson, R. A., Moody, C. J., Marcello, A., Fassati, A. (2014). Heat shock protein 90 controls HIV-1 reactivation from latency. Proc Natl Acad Sci U S A doi:10.1073/pnas.1320178111. Multidisciplinary: Chemistry, Biology, Medicine
Start Year 2012
 
Description Prof. Hiroyuki Osada 
Organisation RIKEN
Country Japan 
Sector Private 
PI Contribution Small molecule screening and drug discovery
Collaborator Contribution Provision of small molecule library "NPDepo"
Impact n/a
Start Year 2011
 
Description Prof. Olivier Schwartz 
Organisation Pasteur Institute, Paris
Country France 
Sector Academic/University 
PI Contribution Provided data and expertise on the role of Hsp90 in HIV-1 infection.
Collaborator Contribution Provided data and expertise on mechanisms contributing to enhanced HIV-1 replication during hyperthermia (fever).
Impact One paper in PLoS Pathogens describing the effect of fever on HIV-1 replication and the role of Hsp90. Roesch, F., Meziane, O., Kula, A., Nisole, S., Porrot, F., Anderson, I., Mammano, F., Fassati, A., Marcello, A., Benkirane, M., Schwartz, O. (2012). Hyperthermia Stimulates HIV-1 Replication. PLoS Pathog 8(7), Artn e1002792 doi:10.1371/journal.ppat. Author URL
Start Year 2011
 
Description Prof. Robin A. Weiss and Dr. Laura McCoy 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Performed novel high through put screening to novel broadly HIV-1 cross-neutralising Llama VHHs
Collaborator Contribution Provided library from vaccinated Llamas and performed molecular analyses of novel VHHs identified by the screening.
Impact Identified three novel broadly cross-neutralising VHHs targeting the CD4-binding site. Determined how such VHHs have emerged following vaccination by deep sequencing. One paper in PLoS Pathogens. McCoy, L.E., Rutten, L., Frampton, D., Anderson, I., Granger, L., Bashford-Rogers, L., Dekkers, G., Strokappe, N.M., Seaman, M.S., Koh, W., Grippo, V., Kliche, A., Verrips, T., Kellam, P., Fassati, A., Weiss, R.A. Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog. In press.?
Start Year 2010
 
Description RIKEN, Prof. Osada 
Organisation RIKEN
Country Japan 
Sector Private 
PI Contribution Small molecule screening and drug discovery
Collaborator Contribution Provision of small molecule library "NPDepo"
Impact None to date
Start Year 2011
 
Description Small Molecule TIN 
Organisation University College London
Department School of Pharmacy
Country United Kingdom 
Sector Academic/University 
PI Contribution The Small Molecule Therapeutic Innovation Network facilitates exchange of ideas and materials for small molecule drug discovery. Further, this collaboration kickstarts many projects across UCL in the area of early stage drug discovery.
Collaborator Contribution Intelectual input, access to instrumentation, access to chemical libraries
Impact None so far
Start Year 2018
 
Description Academic RNAi Screening Meeting 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? Yes
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact The meetings proved very popular and as places are limited, attendees information is made available to other attendees as part of a delegate pack (or can equally be kept confidential if preferred). In addition, for those who stay overnight there is the opportunity to meet up with other delegates in an ad hoc, informal way either on the evening before or after the meeting.

The meetings proved very popular.
Year(s) Of Engagement Activity 2011,2012,2014
URL http://hts.cancerresearchuk.org/rnaiMeeting/index.php
 
Description Academic RNAi Screening meeting 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation workshop facilitator
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact 120 Researchers attended a conference co-organized by Mike Howell, Steve Brown, Emma Shanks and myself. There were talks and panel discussions on this one-day meeting.

The majority of attendants felt that the conference attracted important scientists in the field and many expressed the notion that this will impact the way they plan to do their research. Industrial partners have expressed satisfaction with the level of engagement with researchers, which will give them leads for commercialisation of their products.
Year(s) Of Engagement Activity 2011,2013,2014
 
Description Autophagy UK Network meeting 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact 150 researchers, students, representatives from companies and journals came together to discuss the latest advances in the field of autophagy research in Longon. I was one of two organisers for the entire event.
Year(s) Of Engagement Activity 2017
URL http://autophagy.uk
 
Description Cellectricon workshop 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact -
Year(s) Of Engagement Activity 2012
 
Description ELA Drug Discovery Automation - HCS and Cell Based Assays conference 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? Yes
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Role: Scientific Advisory Board member and chair
Year(s) Of Engagement Activity 2014
 
Description High-Content Biology Lab Opening Symposium 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact 120 researchers attended the Opening Symposium for the High-Content Screening facility, which sparked interest in accessing the facility from academics and industry partners.
Year(s) Of Engagement Activity 2018
 
Description Open day/Science Fair 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact An open day/science fair for MRC funded researchers at UCL - LMCB a principle host and organiser. 500 members of public attended and took part in lectures, demonstrations and other events. Part of MRC Centenary celebrations.

Significant feedback from public impressed by presentations and visibility of MRC funded research.
Year(s) Of Engagement Activity 2013
URL http://www.ucl.ac.uk/lmcb/lmcb-takes-lead-mrc-centenary-celebrations-ucl
 
Description Royal Reception 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact The charitable organization Action Medical Research invited our research team to present at a Royal Reception at Buckingham Palace. HRH Prince Philip was hosting the event and there were approx 50-60 potential charitable donors present who engaged with our research presentation. The donors were very impressed and as a consequence willing to donate funding towards research into childhood diseases. A lot of the people reported that they learned something new and everyone was engaging in discussions around health, scientific research and patient benefit.
Year(s) Of Engagement Activity 2017
 
Description SMi 9th Imaging in Cancer Drug Development conference 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Role: chair
Year(s) Of Engagement Activity 2013
 
Description School Visit (UCL Syddanmark, Denmark) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Schools
Results and Impact 14 Students attended a workshop presentation and a tour of the high-throughput screening facility, which led to very fruitful discussion afterwards.

The students were looking to explore career track options at that time. Several students indicated that they would now consider a career in science rather than as medical assistant.
Year(s) Of Engagement Activity 2014
 
Description School visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact School visit with a tour of the MRC funded screening facility and demonstration of experiments
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
 
Description School visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Approx 20 school children visited the screening lab and were given hands-on introduction to research in my lab.
Year(s) Of Engagement Activity 2019
 
Description Scientific Advisory Board Expert Panel for the Dementia Discovery Fund 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact The Scientific Advisory Board of the Dementia Discovery Fund in collaboration with Alzheimers Research UK, invited me as an expert panel member to discuss the role of Autophagy in Alzheimer's disease. The SAB (composed of leading experts in the pharmaceutical industry and charities) explored the possbility to invest in the development of autophagy modulating drugs for treatment of Alzheimer's disease. This discussion had an immediate impact on funding decisions and the policy of the Dementia Discovery Fund going forward in this area.
Year(s) Of Engagement Activity 2019